Effects of Z-venusol and other pure compounds from medicinal plants on prostate, cervical and breast cancer cells.
Year: 2017
Type: dissertation
Abstract: Introduction \nAccording to recent World Health Organisation (WHO) estimates, cancer causes more deaths \nthan coronary heart diseases globally (GLOBOCAN, 2012). While communicable diseases \nsuch as HIV/AIDS continue to burden African populations, cancer is increasingly recognised \nas a critical public and private health problem in Africa (Igene, 2008). It is estimated that by \n2030, about 112 921 new cases of cancer will be diagnosed in South Africa (Singh et al., 2015). \nThis would represent a 50% increase of new cancer cases as compared to 2012’s estimates by \nthe WHO. \nAlthough there is little doubt about the incidences of cancer, there are, unfortunately, divergent \ntheories in as far as tumourigenesis and the aetiology of cancer. Some researchers hold the \nview that cancer originates from malignant transformation of normal tissue progenitor and stem \ncells (Reya et al., 2001). Others believe that cancer is as a result of mature cells that have \nundergone de-differentiation (Sell, 2004). Notably, latest research has shown that there is a \nstrong association between tissue-specific cancer risk and the lifetime cumulative number of \ncell divisions of tissue or organ-specific stem cells (Tomasetti & Vogelstein, 2015). Although \nthere are still differing views on the origins of cancer, it is widely accepted that this devastating \ndisease occurs as a result of abnormal cell development and is characterised by uncontrollable \ncell proliferation. \nThe majority of currently-available cancer treatments target cell proliferation. However, the \neffectiveness of many cytotoxic drugs, including those that were discovered from plants, is \nlimited by their serious side-effects and cost (Abratt, 2016). Chemotherapeutic agents that were \noriginally discovered from medicinal plants include vinblastine (isolated from Catharanthus \n \nroseus), etoposide (isolated from Podophyllum peltatum), paclitaxel (isolated from Taxus \nbrevifolia) and topotecan and camptothecin (isolated from Camptotheca acumenata). Thus, \nmedicinal plants continue to play a critical role in the management of diseases in the world. \nIn Africa, decoctions, which contain extracts from various medicinal plants (Bruneton, 1995; \nBalunas & Kinghorn, 2005), are widely used for traditional management of many diseases \nincluding cancer. However, apart from subjective oral evidence regarding the effectiveness of \nextracts from various plants, the identity of ingredients, as well as the science and \npharmacology of active compounds found in numerous popular concoctions and decoctions are \nnot known. \nObjectives \nThe main objectives of this study were: \n To assess anti-proliferative potential of three plant-derived-compounds, i.e. hypoxoside, \nent-Beyer-15-en-19-ol and Z-venusol on human cancer cells, namely DU-145 (prostate), \nHeLa (cervical) and MCF-7 (breast) in vitro. \n To determine the type of cell death, i.e. whether a compound with potential causes apoptotic \nor necrotic cell death on both human cancer and normal cell lines (such as MCF-12, \nHMECs and dMVECs). \n To investigate how a potential compound exerts its cytotoxicity. \n \nMaterials and Methods \nInitially dimethylthiazol-diphenyltetrazolium bromide (MTT) assays were conducted to find \nthe concentrations which may inhibit proliferation in prostate (DU-145), cervical (HeLa) and \nbreast (MCF-7) cancer cells. Normal human cell lines, which were used for control purposes, \nwere the primary human mammary epithelial cells (HMECs), MCF-12 and the dermal \nmicrovascular endothelial cells (dMVECs). Initially, cells were exposed for 48 hr to \nhypoxoside, ent-Beyer-15-en-19-ol and Z-venusol, which were isolated from Hypoxis \nhemerocallidea, Helichrysum tenax, and Gunnera perpensa, respectively. The concentrations \nranged from 2.34 μg/mL to 2400 μg/mL, dissolved in cell specific media. In subsequent \nexperiments, the more sensitive sulforhodamine B (SRB) methodology was used, and cells \nwere exposed to Z-venusol for 24 hr, 48 hr and 72 hr, to much lower concentrations, which \nranged from 1.9 μg/mL to 240 μg/mL dissolved in dimethyl sulphoxide (DMSO). \nTo investigate possible pathways of observed cell death, two assays were conducted. These \nwere the fluorescein isothiocyanate (FITC) Annexin V apoptosis detection assay (using the \nFACS Calibur “JO” E5637 flow cytometer for analysis), and the lactate dehydrogenase (LDH) \nassay. To explore possible mechanism(s) of action, the activities of interleukin-6 (IL-6) and \ncyclic adenosine monophosphate (cAMP) were assessed. To investigate the activity of IL-6, \ncells were exposed for 48 hr to various working concentrations of Z-venusol; that is, 37.5 \nμg/mL and 75 μg/mL. To investigate the activity of direct cAMP, cells were exposed for 48 hr \nto various working concentrations of Z-venusol; that is, 37.5 μg/mL, 75 μg/mL, and 150 μg/mL. \nAbsorbance, which is inversely proportional to the concentration of cAMP in both the samples \nand the standards, was measured using a BioRad (Model 3550) microplate reader. Epinephrine \n \n(10 μM) and propranolol (10 μM), were used separately and in combination, added to the \nhighest concentration of Z-venusol for comparison. \nMain Results & Discussion \nHypoxoside resulted in a statistically significant (p < 0.001) 38% and 77% increases in \nproliferation in MCF-7s at concentrations of hypoxoside 1200 μg/mL and 2400 μg/mL, \nrespectively, after 48 hr exposure. In support of the current findings, Xulu (2013) also reported \nthat hypoxoside, and its active derivative known as rooperol, significantly increases cell \nproliferation of both cancer and normal mammary cells in vitro (Xulu, 2013). This was \nconsidered an undesirable finding with regards to the aim of finding a cure for cancer. \nTherefore, no further test were carried out on this compound beyond the initial screening \nstages. \nThe highest concentration (i.e., 2400 μg/mL) of the second compound, that is ent-Beyer-15- \nen-19-ol, decreased proliferation in prostate cancer cells (DU-145) and in breast cancer cells \n(MCF-7) by 6% and 19%, respectively. Interestingly, much lower concentrations, i.e. 4.7 \nμg/mL and 9.4 μg/mL, of ent-beyer-15-en-19-ol significantly (p < 0.05) decreased cell \nproliferation in cervical cancer cells (HeLa) by 37% and 41%, respectively. The differences in \nexpression of vimentin gene, which is over-expressed in HeLa cells and suppressed in MCF- \n7s and DU-145s may explain why this compound showed significant activity only in the \ncervical cancer cells (Oshima, 2002; Satelli & Li, 2011). More importantly, the ability of this \ncompound to significantly inhibit cell proliferation in the HeLa cell line by almost 50% at lower \nconcentrations offers an opportunity for further studies. \n \nThe findings with regards to the third compound, i.e. Z-venusol, were the most exciting. Hence \ninvestigations on it were developed beyond the screening stages. This compound demonstrated \na statistically significant, concentration-dependent, apoptotic inhibitory effect on the \nproliferation of MCF-7 cells, with an IC50 of 53.7 μg/mL after 72 hr exposure, while the highest \nconcentration (250 μg/mL) resulted in 69% inhibition. Both the FITC Annexin V and LDH \nresults suggested that apoptosis contributed to most of the effects observed. Further, there was \nnon-significant inhibition (20%) of HMEC proliferation observed when the concentration of \nZ-venusol was increased beyond 16.6 μg/mL. The highest concentration of Z-venusol used in \nthis study resulted in a statistically significant (p < 0.001) 51% inhibition of IL-6 activity in the \nMCF-7 after 48 hr exposure. None of the Z-venusol concentrations, either alone or in \ncombination with epinephrine, an agonist of the adrenergic receptors, showed any statistically \nsignificant effect on the levels of cAMP in the MCF-7s. Surprisingly, there was a significant \n(p ≤ 0.028) 34% elevation of cAMP levels in cells which were exposed to a combination of Zvenusol \nand propranolol. \nIf Z-venusol was ever able to be used clinically, there might be a need to increase the dose high \nenough for the attainment of desired therapeutic effects with minimal cytotoxicity on normal \ncells, because its potency is much lower than that of cisplatin. Increasing Z-venusol to a \ntherapeutically-effective concentration would be possible as there was no plateauing-off of \ninhibition of proliferation in MCF-7s. It was only in primary normal human mammary \nepithelial cells (HMECs) that formation of “plateaus” was observed. Favourably, this selective \nplateauing-effect might allow the ‘gold-standard’ attainment of the desired cytotoxic effect on \ncancer cells while preserving normal cells at higher concentrations. \n \nThere are no studies with which to directly compare the findings of this study. However, reports \non effects of the extracts of G. perpensa on various other cancer cell lines provide an \nopportunity for comparison. For instance, the results of this research support the findings of \nSimelane and colleagues. They recently reported that G. perpensa extracts caused an inhibition \nof proliferation of hepatocellular carcinoma cells (HepG2) with an IC50 of 222.33 μg/mL and \nhuman embryonic kidney 293 (HEK293) cells, with an IC50 of 279.43 μg/mL both after 48 hr \nof treatment (Simelane et al., 2012). \nConclusion \nZ-venusol, unlike other compounds studied, has a firm
Author: Lehlohonolo J. Mathibe
Institution: University of KwaZulu-Natal
Language: English
Subfield: Organic Chemistry
Field: Chemistry
Domain: Physical Sciences
Open Access status: green
OpenAlex ID: W3177072202
